Abstract
Advanced neuroimaging methods have greatly expanded our understanding of psychiatric disorders by enabling detailed evaluation of brain structure, function, and connectivity. This review synthesizes findings from major psychiatric conditions, including schizophrenia, major depressive disorder, bipolar disorder, obsessive–compulsive disorder (OCD), anxiety disorders, autism spectrum disorder, and attention-deficit/hyperactivity disorder (ADHD). Across disorders, structural mahnetic resonance imaging (MRI) consistently reveals cortical and subcortical abnormalities, while diffusion tensor imaging highlights widespread white-matter dysconnectivity. Functional MRI studies demonstrate disorder specific but overlapping alterations in network activity, particularly involving prefrontal, limbic, and default mode systems. Molecular and spectroscopic imaging add complementary insights into neurotransmitter and metabolic disturbances, including dopaminergic dysfunction in schizophrenia, glutamatergic abnormalities in mood disorders and OCD, GABAergic deficits in anxiety, and excitatory–inhibitory imbalance in autism and ADHD. Although no single imaging marker has sufficient specificity for clinical diagnosis, neuroimaging has substantially advanced mechanistic models of psychiatric illness. Longitudinal and multimodal approaches reveal developmental trajectories, illness progression, and treatment effects, such as lithium-related neurotrophic changes in bipolar disorder or normalization of hyperactive circuits following cognitive behavioral therapy (CBT) in OCD and anxiety disorders. Neuroimaging has transformed the conceptualization of psychiatric disorders from region-specific abnormalities to distributed network and molecular dysfunction. While still largely confined to research, ongoing advances in multimodal integration, large-scale collaborations, and precision imaging approaches hold promise for earlier detection, individualized intervention, and improved patient outcomes.
References
Dabiri M, Dehghani Firouzabadi F, Yang K, Barker PB, Lee RR, Yousem DM, et al. Neuroimaging in schizophrenia: A review article. Front Neurosci. 2022;16:1042814.
Ray S, Pal AK, Kundu PS. A brief review of the neuroimaging modalities in schizophrenia and their scope. Ann Med Sci Res. 2024;3(1):33-38.
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, Barch DM, Beck K, et al. Neuroimaging in schizophrenia: An overview of findings and their implications for synaptic changes. Neuropsychopharmacology. 2023;48(1):151-67.
van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 controls via the ENIGMA consortium. Biol Psychiatry. 2018;84(9):644-54.
Kelly S, Jahanshad N, Zalesky A, Kochunov P, Agartz I, Alloza C, et al. Widespread white matter microstructural differences in schizophrenia across 4322 individuals. Mol Psychiatry. 2018;23(5):1261-9.
Barch DM, Ceaser A. Cognition in schizophrenia: Core psychological and neural mechanisms. Trends Cogn Sci. 2012;16(1):27-34.
Whitfield-Gabrieli S, Ford JM. Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol. 2012;8:49-76.
Townsend L, Kobylecki C, Ebdrup BH, Jørgensen KN, Nordentoft M, Glenthøj B, et al. Brain glucose metabolism in schizophrenia: A systematic review and meta-analysis of 18FDG-PET studies. Psychol Med. 2022;53(12):4880-97.
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III. Schizophr Bull. 2009;35(3):549-62.
Sui J, Adali T, Pearlson GD, Calhoun VD. Multimodal neuroimaging data fusion for schizophrenia research. Front Hum Neurosci. 2018;12:27.
Onwordi EC, Halff EF, Whitehurst T, Mansur A, Cotel MC, Wells L, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun. 2020;11:246.
Vieira S, Gong Q, Scarpazza C, Lui S, Huang X, Crespo-Facorro B, et al. Using machine learning and structural neuroimaging to detect first episode psychosis: Reconsidering the evidence. Schizophr Bull. 2020;46(1):17-26.
Sun D, Phillips L, Velakoulis D, Yung A, McGorry PD, Wood SJ, et al. Progressive brain structural changes mapped as psychosis develops in ‘at risk’ individuals. Schizophr Res. 2009;108(1-3):85-92.
Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes. Arch Gen Psychiatry. 2011;68(2):128-37.
Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, et al. Detecting neuroimaging biomarkers for schizophrenia: A meta-analysis of multivariate pattern recognition studies. Neuropsychopharmacology. 2015;40(7):1742-51.
Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders. Brain Struct Funct. 2008;213(1-2):93-118.
Kupfer DJ, Phillips ML. Imaging in major depressive disorder. Dialogues Clin Neurosci. 2013;15(4):443-61.
Schmaal L, Hibar DP, Sämann PG, Hall GB, Baune BT, Jahanshad N, et al. Cortical abnormalities in adults and adolescents with major depression based on 20 international cohorts. Mol Psychiatry. 2017;22(6):900-9.
Frodl T, Jäger M, Smajstrlova I, Born C, Bottlender R, Palladino T, et al. Reduced hippocampal volume correlates with duration of illness in major depression. Mol Psychiatry. 2008;13(11):1090-101.
Siegle GJ, Thompson W, Carter CS, Steinhauer SR, Thase ME. Increased amygdala and decreased dorsolateral prefrontal activation in depression. Am J Psychiatry. 2007;164(6):920-7.
Mulders PC, van Eijndhoven PF, Schene AH, Beckmann CF, Tendolkar I. Resting-state functional connectivity in major depressive disorder: A review. Neurosci Biobehav Rev. 2015;56:330-44.
Gong Q, He Y. Depression, neuroimaging and connectomics: A selective overview. Biol Psychiatry. 2015;77(3):223-35.
Nugent AC, Farmer C, Evans JW, Zarate CA Jr. Multimodal imaging reveals basal ganglia contribution to mood in depression. Neuropsychopharmacology. 2019;44(4):823-32.
Wu MJ, Mwangi B, Bauer IE, Passos IC, Sanches M, Zunta-Soares GB, et al. Predicting treatment response in depression: A review of neuroimaging findings. CNS Spectr. 2020;25(5):539-52.
Siegle GJ, Carter CS, Thase ME. Amygdala activity predicts response to cognitive behavioral therapy in unipolar depression. Biol Psychiatry. 2012;71(8):713-9.
Arnone D, McIntosh AM, Ebmeier KP, Munafò MR, Anderson IM. Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses. Eur Neuropsychopharmacol. 2012;22(1):1-16.
Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies in bipolar disorder: Toward a new conceptualization. Am J Psychiatry. 2014;171(8):829-43.
Goodkind M, Eickhoff SB, Oathes DJ, Jiang Y, Chang A, Jones-Hagata LB, et al. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry. 2015;72(4):305-15.
Hibar DP, Westlye LT, Doan NT, Jahanshad N, Cheung JW, Ching CRK, et al. Cortical abnormalities in bipolar disorder: An ENIGMA consortium analysis. Mol Psychiatry. 2018;23(9):2271-82.
Hibar DP, Westlye LT, van Erp TGM, Rasmussen J, Leonardo CD, Faskowitz J, et al. Subcortical volumetric abnormalities in bipolar disorder. Mol Psychiatry. 2016;21(12):1710-6.
Bora E, Fornito A, Yücel M, Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in pediatric bipolar disorder. Psychol Med. 2010;40(11):1899-908.
Nortje G, Stein DJ, Radua J, Mataix-Cols D, Horn N. Systematic review and voxel-based meta-analysis of DTI in BD. J Affect Disord. 2013;150(2):192-200.
Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, et al. Lithium increases NAA/gray matter in bipolar disorder: MRI/MRS evidence. Biol Psychiatry. 2000;48(1):1-8.
Chen CH, Lennox B, Jacob R, Calder A, Lupson V, Bisbrown-Chippendale R, et al. Functional abnormalities of emotional processing in BD: Meta-analysis of fMRI studies. Biol Psychiatry. 2011;70(4):311-7.
Meda SA, Wang Z, Ivleva EI, Poudyal G, Keshavan MS, Tamminga CA, et al. Resting-state functional dysconnectivity in BD and effects of mood state. Biol Psychiatry. 2014;76(10):807-16.
Brooks JO, Vizueta N, Penfold C, Townsend JD, Bookheimer SY, Altshuler LL. Prefrontal and limbic metabolic changes across mood states in BD: FDG-PET. Bipolar Disord. 2015;17(8):850-61.
Sarchiapone M, Carli V, Camardese G, Cuomo C, Di Giuda D, Calcagni ML, et al. Serotonin/dopamine imaging in BD: A systematic review. Eur Neuropsychopharmacol. 2018;28(10):1095-109.
Sui J, Qi S, van Erp TGM, Bustillo JR, Jiang R, Lin D, et al. Multimodal fusion imaging in mood disorders. Trends Cogn Sci. 2020;24(3):227-40.
Yuksel C, Öngür D. MR spectroscopy studies in mood disorders: A meta-analysis. Biol Psychiatry. 2010;68(9):785-94.
Mwangi B, Ebmeier KP, Matthews K, Steele JD. Neuroimaging-based classification of BD: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2012;36(1):58-70.
Abbott CC, Jones T, Lemke NT, Gallegos P, McClintock SM, Mayer AR, et al. Hippocampal and amygdala volume changes following ECT in mood disorders. J ECT. 2014;30(4):196-202.
Stein DJ, Costa DLC, Lochner C, Miguel EC, Reddy YCJ, Shavitt RG, et al. Obsessive–compulsive disorder. Nat Rev Dis Primers. 2019;5:52.
Saxena S, Rauch SL. Functional neuroimaging and the neuroanatomy of obsessive–compulsive disorder. Psychiatr Clin North Am. 2000;23(3):563-86.
Rotge JY, Guehl D, Dilharreguy B, Tignol J, Bioulac B, Burbaud P, et al. Provocation of obsessive–compulsive symptoms: A quantitative meta-analysis of functional neuroimaging studies. Arch Gen Psychiatry. 2008;65(7):701-11.
de Wit SJ, Alonso P, Schweren L, Mataix-Cols D, Lochner C, Menchón JM, et al. Multicenter voxel-based morphometry mega-analysis in obsessive–compulsive disorder. Am J Psychiatry. 2014;171(3):340-9.
Piras F, Piras F, Caltagirone C, Spalletta G. Brain white matter microstructure in obsessive–compulsive disorder: A TBSS meta-analysis. J Affect Disord. 2013;151(2):438-48.
Harrison BJ, Soriano-Mas C, Pujol J, Ortiz H, López-Solà M, Hernández-Ribas R, et al. Altered corticostriatal functional connectivity in obsessive–compulsive disorder. Arch Gen Psychiatry. 2009;66(11):1189-200.
Stern ER, Fitzgerald KD, Welsh RC, Abelson JL, Taylor SF. Hyperactive error responses and anterior cingulate cortex hyperactivation in OCD. Biol Psychiatry. 2011;69(7):583-91.
Gürsel DA, Avram M, Sorg C, Brandl F. Distinct network-level dysconnectivity in obsessive–compulsive disorder: A meta-analysis of resting-state fMRI studies. Hum Brain Mapp. 2018;39(7):2733-49.
Baxter LR Jr, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, et al. Caudate glucose metabolic rate changes with treatment in OCD. Arch Gen Psychiatry. 1992;49(9):681-9.
Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME. Systematic changes of cerebral glucose metabolic rate after successful behavior modification treatment of OCD. Arch Gen Psychiatry. 1996;53(2):109-13.
Brennan BP, Rauch SL, Jensen JE, Pope HG Jr. A critical review of proton MRS studies of glutamatergic metabolites in OCD. Psychiatry Res Neuroimaging. 2013;211(1):1-11.
Denys D, Mantione M, Figee M, van den Munckhof P, Koerselman F, Westenberg H, et al. Deep brain stimulation of the nucleus accumbens for treatment-refractory OCD: A randomized crossover trial. Arch Gen Psychiatry. 2010;67(10):1091-8.
Figee M, Luigjes J, Smolders R, Valencia-Alfonso CE, van Wingen G, de Kwaasteniet B, et al. Deep brain stimulation restores frontostriatal network activity in OCD. Nat Neurosci. 2013;16(4):386-7.
Carmi L, Tendler A, Bystritsky A, Hollander E, Blumberger DM, Daskalakis J, et al. Efficacy and safety of deep TMS over the medial prefrontal cortex and ACC for OCD: A randomized controlled study. Am J Psychiatry. 2018;175(1):77-86.
Etkin A, Wager TD. Functional neuroimaging of anxiety: An updated meta-analysis of emotional processing in anxiety disorders. Am J Psychiatry. 2007;164(10):1476-88.
Sylvester CM, Corbetta M, Raichle ME, Rodebaugh TL, Schlaggar BL, Sheline YI, et al. Functional network dysfunction in anxiety and anxiety disorders. Trends Cogn Sci. 2012;16(4):221-9.
Brühl AB, Delsignore A, Komossa K, Weidt S. Neuroimaging in social anxiety disorder: A meta-analytic review. PLoS One. 2014;9(3):e93400.
Kim MJ, Whalen PJ. The structural integrity of an amygdala–prefrontal pathway predicts trait anxiety. Nat Neurosci. 2009;12(11):1367-8.
Fox AS, Shackman AJ. The central extended amygdala in fear and anxiety: Closing the gap between mechanistic and neuroimaging research. Biol Psychiatry. 2019;85(12):1061-9.
Bishop SJ. Neurocognitive mechanisms of anxiety: An integrative account of prefrontal–subcortical pathways. Trends Cogn Sci. 2007;11(7):307-16.
McTeague LM, Goodkind MS, Etkin A. Transdiagnostic impairment of cognitive control networks across internalizing psychopathology. Trends Cogn Sci. 2016;20(7):452-64.
Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased benzodiazepine-GABA_A receptor binding in panic disorder: A [11C]-flumazenil PET study. Arch Gen Psychiatry. 1998;55(8):715-20.
Nutt DJ, Malizia AL. New insights into the role of the GABA_A–benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390-6.
Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, et al. Reductions in occipital cortex GABA levels in panic disorder: A 1H-MRS study. Am J Psychiatry. 2001;158(1):77-9.
Goldin PR, Gross JJ, Heimberg RG. Functional changes in amygdala–prefrontal circuitry after cognitive behavioral therapy of social anxiety disorder. Biol Psychiatry. 2013;73(9):843-51.
Diefenbach GJ, Bragdon LB, Goethe JW, Bui E, Ahern DK, Pizzagalli DA, et al. Mechanism-based rTMS for generalized anxiety disorder: A randomized, sham-controlled trial. J Affect Disord. 2016;202:137-44.
Dilkov D, Hawken ER, Kaludiev E, Milev R. Repetitive transcranial magnetic stimulation for generalized anxiety disorder: A randomized, double-blind pilot study. J Nerv Ment Dis. 2017;205(11):913-8.
Ecker C, Bookheimer SY, Murphy DGM. Neuroimaging in autism spectrum disorder: Brain structure and function. Autism Res. 2015;8(4):367-92.
Di Martino A, Yan CG, Li Q, Denio E, Castellanos FX, Alaerts K, et al. The autism brain imaging data exchange: Toward a large-scale evaluation of the intrinsic brain architecture in ASD. Mol Psychiatry. 2014;19(6):659-67.
Ameis SH, Catani M. Altered white matter connectivity as a neural substrate of autism spectrum disorders: A DTI review. Mol Autism. 2015;6:51.
Hazlett HC, Gu H, Munsell BC, Kim SH, Styner M, Wolff JJ, et al. Early brain development in infants at high risk for autism spectrum disorder. Nature. 2017;542(7641):348-51.
Just MA, Keller TA, Malave VL, Kana RK, Varma S. Autism as a neural systems disorder: A theory of frontal–posterior underconnectivity. Neurosci Biobehav Rev. 2012;36(4):1292-313.
Nomi JS, Uddin LQ. Developmental changes in large-scale network connectivity in autism. Neuroimage Clin. 2015;7:732-41.
Aoki Y, Cortese S, Castellanos FX. MRS studies of GABA and glutamate in autism spectrum disorders: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2012;22(7):411-27.
Ajram LA, Horder J, Mendez MA, Galanopoulou A, Brennan LP, Ahmad J, et al. Reduced GABAA receptors in autism: [11C]Ro15-4513 PET evidence of lower α5-subunit binding. Cereb Cortex. 2017;27(7):3194-204.
Castellanos FX, Proal E. Large-scale brain systems in ADHD: Beyond the prefrontal-striatal model. Trends Cogn Sci. 2012;16(1):17-26.
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP, et al. Toward systems neuroscience of ADHD: A meta-analysis of functional neuroimaging studies. Biol Psychiatry. 2012;71(3):194-202.
Hoogman M, Bralten J, Hibar DP, Mennes M, Zwiers MP, Schweren LS, et al. Subcortical brain volume differences in participants with ADHD: A cross-sectional mega-analysis. Lancet Psychiatry. 2017;4(4):310-9.
Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA. 2007;104(49):19649-54.
Hoogman M, Muetzel RL, Guimaraes JP, Shumskaya E, Mennes M, Zwiers MP, et al. Brain imaging of the cortex in ADHD: ENIGMA ADHD Working Group. Am J Psychiatry. 2019;176(7):531-42.
van Ewijk H, Heslenfeld DJ, Zwiers MP, Buitelaar JK, Oosterlaan J. Diffusion tensor imaging in ADHD: A systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2012;51(10):943-67.
Rubia K, Smith AB, Brammer MJ, Taylor E. Right inferior frontal cortex dysfunction in ADHD during inhibitory control. Biol Psychiatry. 2003;54(12):1345-51.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. Meta-analysis of fMRI studies of inhibitory control in ADHD. JAMA Psychiatry. 2013;70(2):185-98.
Fair DA, Posner J, Nagel BJ, Bathula D, Dias TG, Mills KL, et al. Atypical default network connectivity in youth with ADHD. Proc Natl Acad Sci USA. 2010;107(40):18669-74.
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. Methylphenidate’s effects on dopamine and functional circuits: PET evidence. J Neurosci. 2009;29(15):6008-17.
Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005;57(11):1293-300.
Vidor MV, Panzenhagen AC, Martins AR, Cupertino RB, Bandeira CE, Picon FA, et al. Emerging findings of glutamate-glutamine imbalance in the medial prefrontal cortex in attention deficit/hyperactivity disorder: systematic review and meta-analysis of spectroscopy studies. Eur Arch Psychiatry Clin Neurosci. 2022;272(8):1395-411.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Çukurova Journal of Mental Health